November 28, 2016 - By Dolores Ford · 0 Comments
The stock of Cambrex Corporation (NYSE:CBM) registered an increase of 4.44% in short interest. CBM’s total short interest was 1.13 million shares in November as published by FINRA. Its up 4.44% from 1.09M shares, reported previously. With 250,000 shares average volume, it will take short sellers 5 days to cover their CBM’s short positions. The short interest to Cambrex Corporation’s float is 3.58%. About 111,562 shares traded hands. Cambrex Corporation (NYSE:CBM) has risen 9.90% since April 25, 2016 and is uptrending. It has outperformed by 3.89% the S&P500.
Cambrex Corporation is a life sciences company. The company has a market cap of $1.58 billion. The Firm provides services and products for the development and commercialization of new and generic therapeutics. It has a 24.14 P/E ratio. The Firm supplies its services and products across the world to generic pharmaceutical companies.
Insitutional Activity: The institutional sentiment is 1.03 in Q2 2016. Its the same as in 2016Q1. The ratio is without change, as 22 funds sold all Cambrex Corporation shares owned while 76 reduced positions. only 31 funds bought stakes while 70 increased positions. They now own 28.84 million shares or 4.08% less from 30.07 million shares in 2016Q1.
Waddell Reed Fin, a Kansas-based fund reported 420,600 shares. Swiss Commercial Bank holds 0% of its portfolio in Cambrex Corporation (NYSE:CBM) for 54,600 shares. Thompson Davis Com holds 0.08% of its portfolio in Cambrex Corporation (NYSE:CBM) for 1,001 shares. The Illinois-based Envestnet Asset Mngmt Incorporated has invested 0% in Cambrex Corporation (NYSE:CBM). Us Bank De holds 0.01% or 41,422 shares in its portfolio. Analytic Invsts Ltd Company has 0.01% invested in the company for 24,417 shares. Moreover, Jpmorgan Chase And has 0% invested in Cambrex Corporation (NYSE:CBM) for 82,223 shares. Oberweis Asset Mgmt owns 114,795 shares or 1.76% of their US portfolio. Tradewinds Glob has invested 0.02% of its portfolio in Cambrex Corporation (NYSE:CBM). Tealwood Asset Management holds 44,385 shares or 1.03% of its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% of its portfolio in Cambrex Corporation (NYSE:CBM) for 719 shares. Clarivest Asset Mngmt Lc has 51,237 shares for 0.08% of their US portfolio. First Citizens Bank & Trust & Tru, a North Carolina-based fund reported 12,151 shares. Hutchin Hill Cap L P has 29,600 shares for 0.05% of their US portfolio. Axiom Intl Investors Ltd Liability Co De holds 0.18% of its portfolio in Cambrex Corporation (NYSE:CBM) for 122,222 shares.
Insider Transactions: Since June 8, 2016, the stock had 0 buys, and 4 insider sales for $4.12 million net activity. KLOSK STEVEN M also sold $2.54M worth of Cambrex Corporation (NYSE:CBM) on Wednesday, November 9. Another trade for 4,142 shares valued at $217,331 was sold by KORB WILLIAM B. Shares for $1.17M were sold by SARGEN GREGORY.
Out of 4 analysts covering Cambrex Corp (NYSE:CBM), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cambrex Corp has been the topic of 4 analyst reports since July 21, 2015 according to StockzIntelligence Inc. Singular Research maintained Cambrex Corporation (NYSE:CBM) on Thursday, February 11 with “Buy” rating. The firm has “Overweight” rating given on Monday, November 7 by First Analysis. The rating was initiated by Stephens with “Overweight” on Tuesday, July 21.
Cambrex Corporation (Cambrex), incorporated on October 11, 1983, is a life sciences company. The Firm provides services and products for the development and commercialization of new and generic therapeutics. The Firm supplies its services and products across the world to generic pharmaceutical companies. Cambrex operates through three divisions, which are manufacturing facilities. The Company’s manufacturing facilities are located in the Europe and the United States.
More recent Cambrex Corporation (NYSE:CBM) news were published by: Fool.com which released: “Pharma Manufacturer Cambrex Corporation Rose as Much as 19.3% on Strong Earnings” on November 04, 2016. Also Globenewswire.com published the news titled: “Claes Glassell Appointed to the Board of Directors of Cambrex Corporation” on March 16, 2016. Seekingalpha.com‘s news article titled: “Cambrex Corporation: Exciting Time Ahead For This Biotech Company” with publication date: March 24, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Dolores Ford